Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
8 hedge funds and large institutions have $13.7M invested in Celyad Oncology SA American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
29% less capital invested
Capital invested by funds: $19.3M → $13.7M (-$5.67M)
33% less funds holding
Funds holding: 12 → 8 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$897K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$608K |
| 3 |
Morgan Stanley
New York
|
+$89.4K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$4.32K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$1.05M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$155K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$21K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.1K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
-$7K |
CYAD Hedge Fund Activity: Q4 2018 in Review
8 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q4 2018, worth a combined $13.7M — down 29% from $19.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CYAD and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, adding an estimated $897K. The largest seller was Stanley-Laman Group, exiting entirely with an estimated $1.05M sold.
- 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q4 2018, down from 12 in Q3 2018.
- Funds reported $13.7M of Celyad Oncology SA American Depositary Shares stock for Q4 2018, down 29% quarter-over-quarter.
- 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q4 2018 and 5 closed out, a net change of -4 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q4 2018 was Millennium Management, an estimated $897K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q4 2018 was Stanley-Laman Group, an estimated $1.05M sold.
Based on aggregated 13F filings for Q4 2018.